{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:48:10Z","timestamp":1791809290601,"version":"4.3.4"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Rituximab is widely used for autoimmune nephropathy. It depletes B cells, potentially increasing infection risk. Tuberculosis is a rare but severe complication of rituximab treatment. We report a case of liver tuberculosis in a patient with C1q nephropathy with Minimal Change Disease (MCD) treated with rituximab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>In March 2023, an 81-year-old male patient was admitted to Shaoxing Second Hospital with a 2-month history of bilateral lower extremity edema. He was diagnosed with C1q nephropathy with MCD through renal biopsy. After treatment with 2\u202fg rituximab, his proteinuria was relieved. In October 2024, due to B-cell rebound, 0.5\u202fg of rituximab was added. In December 2023, the patient visited our hospital due to a 7-day fever. Abdominal ultrasound revealed a non-uniform hypoechoic liver mass suspected to be an abscess. Empirical antibiotic treatment was ineffective and the condition worsened. A liver biopsy was immediately performed, and the pathology showed characteristic granulomatous inflammation and patchy coagulative necrosis. The patient was ultimately diagnosed with hepatic tuberculosis and received a 1-year anti-tuberculosis treatment, including rifampicin 450\u202fmg qd, isoniazid 300\u202fmg qd, pyrazinamide 1,500\u202fmg qd, and ethambutol 1,000\u202fmg qd. The patient\u2019s temperature returned to normal and abdominal pain was relieved on the third day of treatment. Two months later, a follow-up ultrasound showed a reduction in the left lobe liver mass, and an 8-month CT scan showed complete disappearance of the mass. The patient is currently under follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Rituximab may be an effective treatment option for C1q nephropathy with MCD. Although the risk of infection with rituximab is relatively low, rare infections such as tuberculosis still need to be vigilant, especially in elderly or immunocompromised patients. Additionally, we recommend routine screening for latent tuberculosis in elderly patients with nephropathy and hypogammaglobulinemia before rituximab treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1621723","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:46:54Z","timestamp":1756446414000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Hepatic tuberculosis induced by rituximab treatment for C1q nephropathy with minimal change disease: a case report"],"prefix":"10.3389","volume":"12","author":[{"given":"Huifang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"583565","DOI":"10.3389\/fendo.2020.583565","article-title":"Use of rituximab after orbital decompression surgery in two grave's ophthalmopathy patients progressing to optic neuropathy","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"854","DOI":"10.2215\/CJN.0000000694","article-title":"Predicting remission in anti-PLA2R antibody-associated membranous nephropathy: a secondary analysis of the GEMRITUX, MENTOR and STARMEN trials","volume":"20","author":"Barbour","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/tri.12616","article-title":"ABO desensitization affects cellular immunity and infection control after renal transplantation","volume":"28","author":"Schachtner","year":"2015","journal-title":"Transpl Int"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1600-6143.2009.02785.x","article-title":"Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients","volume":"10","author":"Kamar","year":"2010","journal-title":"Am J Transplant"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/ckj\/sfw101","article-title":"Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease","volume":"10","author":"Trivin","year":"2017","journal-title":"Clin Kidney J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3389\/fimmu.2019.01519","article-title":"Recombinant BCG with bacterial signaling molecule cyclic di-AMP as endogenous adjuvant induces elevated immune responses after mycobacterium tuberculosis infection","volume":"10","author":"Ning","year":"2019","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e60221","DOI":"10.1128\/jcm.00602-21","article-title":"The brief case: a real pain in the testicle-a case of extrapulmonary mycobacterium tuberculosis","volume":"60","author":"Plourde","year":"2022","journal-title":"J Clin Microbiol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1177\/0961203317722849","article-title":"Cerebral tuberculosis in a patient with systemic lupus erythematosus following cyclophosphamide treatment: a case report","volume":"27","author":"Cooray","year":"2018","journal-title":"Lupus"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2147\/OARRR.S268852","article-title":"Tuberculosis arthritis in the wrist while using rituximab for rheumatoid arthritis treatment","volume":"12","author":"Ulusoy","year":"2020","journal-title":"Open Access Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1097\/MJT.0000000000001257","article-title":"Rituximab-associated reactivation of tuberculosis","volume":"29","author":"Sohal","year":"2020","journal-title":"Am J Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.6002\/ect.2014.0156","article-title":"Rituximab therapy and infection risk in pediatric renal transplant patients","volume":"14","author":"Gulleroglu","year":"2016","journal-title":"Exp Clin Transplant"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1681\/ASN.2007080929","article-title":"Pathology, clinical presentations, and outcomes of C1q nephropathy","volume":"19","author":"Vizjak","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1182\/bloodadvances.2021005291","article-title":"High risk of relapsed disease in patients with NK\/T-cell chronic active Epstein-Barr virus disease outside of Asia","volume":"6","author":"Davila Saldana","year":"2022","journal-title":"Blood Adv"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jaci.2021.03.041","article-title":"Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients","volume":"148","author":"Labrosse","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"E1294","DOI":"10.1210\/jc.2013-3207","article-title":"Rituximab (Rituxan) therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R(+) T cells","volume":"99","author":"McCoy","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2169\/internalmedicine.3357-23","article-title":"Late-onset neutropenia after rituximab treatment for MPO-ANCA-associated Vasculitis","volume":"64","author":"Watanabe","year":"2025","journal-title":"Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"8909834","DOI":"10.1155\/2017\/8909834","article-title":"Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics","volume":"2017","author":"Cantini","year":"2017","journal-title":"Mediat Inflamm"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e13963","DOI":"10.1111\/tid.13963","article-title":"Risk of tuberculosis among renal transplant recipients receiving rituximab therapy","volume":"24","author":"Chandrashekhar","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e50581","DOI":"10.7759\/cureus.50581","article-title":"Prevalence of latent tuberculosis infection among rheumatology patients and management practices in the united arab emirates: A Single-Center retrospective cohort study","volume":"15","author":"Al Nokhatha","year":"2023","journal-title":"Cureus"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s13244-015-0440-y","article-title":"Hepatic tuberculosis: a multimodality imaging review","volume":"6","author":"Kakkar","year":"2015","journal-title":"Insights Imaging"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"321.e11","DOI":"10.1016\/j.crad.2017.10.016","article-title":"Imaging appearances of hepatic tuberculosis: experience with 12 patients","volume":"73","author":"Ch'Ng","year":"2018","journal-title":"Clin Radiol"},{"key":"ref24","volume-title":"Consolidated guidelines on tuberculosis: Module 4: treatment \u2013 Tuberculosis care and support [Internet]","year":"2022"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12879-015-0944-6","article-title":"A systematic review of hepatic tuberculosis with considerations in human immunodeficiency virus co-infection","volume":"15","author":"Hickey","year":"2015","journal-title":"BMC Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/ajcp\/78.1.29","article-title":"Nonsystemic mesangiopathic glomerulonephritis with \"full house\" immunofluorescence. Pathological and clinical observation in five patients","volume":"78","author":"Jones","year":"1982","journal-title":"Am J Clin Pathol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/s0272-6386(85)80150-5","article-title":"C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome","volume":"6","author":"Jennette","year":"1985","journal-title":"Am J Kidney Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s00467-004-1810-8","article-title":"C1q nephropathy: features at presentation and outcome","volume":"20","author":"Lau","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00467-005-2024-4","article-title":"C1q nephropathy with asymptomatic urine abnormalities","volume":"20","author":"Nishida","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1046\/j.1523-1755.2003.00218.x","article-title":"C1q nephropathy: a variant of focal segmental glomerulosclerosis","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/s0272-6386(12)80114-4","article-title":"C1q nephropathy: a pediatric clinicopathologic study","volume":"18","author":"Iskandar","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00467-009-1429-x","article-title":"C1q nephropathy in the pediatric population: pathology and pathogenesis","volume":"25","author":"Wenderfer","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12882-022-02870-z","article-title":"1,25-dihydroxyvitamin D3 ameliorates lupus nephritis through inhibiting the NF-\u03baB and MAPK signalling pathways in MRL\/lpr mice","volume":"23","author":"Li","year":"2022","journal-title":"BMC Nephrol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4103\/ijn.IJN_353_17","article-title":"C1q nephropathy in a patient of neurofibromatosis type 1: a rare case report","volume":"29","author":"Varyani","year":"2019","journal-title":"Indian J Nephrol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/ndt\/gfh139","article-title":"Distinguishing C1q nephropathy from lupus nephritis","volume":"19","author":"Sharman","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00467-008-0939-2","article-title":"A single-center study of C1q nephropathy in children","volume":"24","author":"Roberti","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"490413","DOI":"10.1155\/2015\/490413","article-title":"C1q nephropathy: the unique underrecognized pathological entity","volume":"2015","author":"Devasahayam","year":"2015","journal-title":"Anal Cell Pathol (Amst)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1159\/000063313","article-title":"De novo C1q nephropathy in the renal allograft of a kidney pancreas transplant recipient: BK virus-induced nephropathy?","volume":"92","author":"Isaac","year":"2002","journal-title":"Nephron Clin Pract"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e215217","DOI":"10.1371\/journal.pone.0215217","article-title":"C1q nephropathy in adults is a form of focal segmental glomerulosclerosis in terms of clinical characteristics","volume":"14","author":"Kim","year":"2019","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00467-008-1058-9","article-title":"C1q nephropathy and minimal change nephrotic syndrome","volume":"24","author":"Wong","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00467-013-2692-4","article-title":"C1q nephropathy in children: clinical characteristics and outcome","volume":"29","author":"Gunasekara","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"568773","DOI":"10.3389\/fped.2020.568773","article-title":"Case report: complete remission of c1q nephropathy treated with a single low-dose rituximab, a reality or coincidence?","volume":"8","author":"Ma","year":"2020","journal-title":"Front Pediatr"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/nep.12757","article-title":"Successful treatment of C1q nephropathy with CD19 targeted rituximab therapy","volume":"22","author":"Ramachandran","year":"2017","journal-title":"Nephrology (Carlton)"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1621723\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:46:55Z","timestamp":1756446415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1621723\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":43,"alternative-id":["10.3389\/fmed.2025.1621723"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1621723","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"article-number":"1621723"}}